Boston Scientific Corporation
Analysis
EP and WATCHMAN carried Boston Scientific's growth and both reversed inside a few months. After repeated guidance cuts, the company now leans on a steady base business and $500 million of annual cost cuts until the next product wave arrives. How much of the 2026 guidance cut came from WATCHMAN versus EP?
- The two engines that carried growth are now the drag.
EP grew more than 60% a year ago and single digits in Q2 FY2026; WATCHMAN slipped from nearly 30% to low single digits. Management cut full-year guidance twice, admitting it "did not anticipate the degree of competitive share movement." How much of the U.S. EP slowdown is share loss versus a smaller market?
- The rest of the business now has to carry the company.
Interventional cardiology, neuromodulation, endoscopy and IO are still growing around 6%, and ICVT, as management now calls it, is the company's strongest future growth driver. Urology is the exception, flat and not recovering before 2027. Which ICVT products are producing the double-digit growth?
- Cost cuts are doing the work growth used to do.
WATCHMAN and EP losses strip out the mix that lifts profit, so 2026 margin expansion was cut to almost nothing. A restructuring targets $500 million of savings by 2029 — spending now for launches that pay later.
- Diversified base businessThe bull case starts with most of revenue outside the two slowing franchises, where steady demand and growth in several units give management time to repair WATCHMAN and EP.
- Product cycle and acquisitionsA dense product cycle and acquisitions in vascular, cardiac rhythm and neuromodulation are expected to add new growth drivers before the current portfolio matures.
- WATCHMAN clinical evidencePositive CHAMPION data and a large untreated population support the view that WATCHMAN can return to growth once referral patterns and hospital capacity adjust.
- WATCHMAN referral slowdownThe bear case is that recent clinical evidence has changed referral habits for stand-alone WATCHMAN, and management assumes no recovery until those patterns visibly change.
- EP competitive share lossIn electrophysiology, several large competitors are now taking share in a highly penetrated U.S. market, so Boston Scientific's leading position may not translate into above-market growth.
- Repeated guidance cutsManagement has cut its full-year outlook more than once and now points to limited earnings growth next year, which weakens confidence in the long-range targets.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$15K | Aug 28 | Oct 8 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Aug 17 | Oct 8 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Aug 10 | Oct 8 |
Donald Trump Republican · Executive | Purchase | ≥$50K | Jul 27 | Sep 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Jul 24 | Sep 22 |
Congressional trading data provided by QuiverQuant
How Boston Scientific turned $20.1B of revenue into $3.6B of operating income.
| Revenue | ||
|---|---|---|
| Cardiovascular | $13.3B | ▲ 23.35% YoY |
| MedSurg | $6.8B | ▲ 13.95% YoY |
| Total revenue | $20.1B | |
| Gross profit | $13.9B | 69.0% |
| Operating income | $3.6B | 18.0% |